BEONE MEDICINES LTD-ADR (ONC) Stock Price & Overview
NASDAQ:ONC • US07725L1026
The current stock price of ONC is 285.3 USD. Today ONC is down by -4.55%. In the past month the price decreased by -18.78%. In the past year, price increased by 10.07%.
ONC Key Statistics
- Market Cap
- 31.571B
- P/E
- 10.16
- Fwd P/E
- 41.02
- EPS (TTM)
- 28.09
- Dividend Yield
- N/A
ONC Stock Performance
ONC Stock Chart
ONC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ONC. When comparing the yearly performance of all stocks, ONC turns out to be only a medium performer in the overall market: it outperformed 40.12% of all stocks.
ONC Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to ONC. ONC has only an average score on both its financial health and profitability.
ONC Earnings
On February 26, 2026 ONC reported an EPS of 55.02 and a revenue of 10.25B. The company beat EPS expectations (477.76% surprise) and missed revenue expectations (-5.26% surprise).
ONC Forecast & Estimates
15 analysts have analysed ONC and the average price target is 365.13 USD. This implies a price increase of 27.98% is expected in the next year compared to the current price of 285.3.
For the next year, analysts expect an EPS growth of 145.86% and a revenue growth 41.02% for ONC
ONC Groups
Sector & Classification
ONC Financial Highlights
Over the last trailing twelve months ONC reported a non-GAAP Earnings per Share(EPS) of 28.09. The EPS increased by 482.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.28% | ||
| ROE | -0.52% | ||
| Debt/Equity | 0.23 |
ONC Ownership
ONC Latest News, Press Relases and Analysis
ONC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.19 | 398.492B | ||
| AMGN | AMGEN INC | 16.11 | 198.265B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.66 | 121.459B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 78.932B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.52 | 42.071B | ||
| INSM | INSMED INC | N/A | 30.073B | ||
| BIIB | BIOGEN INC | 11.5 | 27.136B | ||
| NTRA | NATERA INC | N/A | 26.973B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.84 | 23.353B | ||
| MRNA | MODERNA INC | N/A | 21.086B | ||
| EXAS | EXACT SCIENCES CORP | 339.75 | 19.713B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.84B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ONC
Company Profile
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
Company Info
IPO: 2016-03-02
BEONE MEDICINES LTD-ADR
c/o BeOne Medicines I GmbH, Aeschengraben 27
Basel BASEL-STADT CH
Employees: 11000
Phone: 41616851900
BEONE MEDICINES LTD-ADR / ONC FAQ
What does BEONE MEDICINES LTD-ADR do?
BeOne Medicines AG is a CH-based company operating in Biotechnology industry. The company is headquartered in Basel, Basel-Stadt and currently employs 11,075 full-time employees. The company went IPO on 2016-03-02. BeOne Medicines AG, formerly BeiGene, Ltd., is a global oncology company engaged in discovering and developing treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, the Company is engaged in the development of its diverse pipeline of novel therapeutics. Its products include Brukinsa, Tevimbra and Pamiparib. Brukinsa is an orally available, small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Tevimbra is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. The company is designed to minimize binding to Fc-gamma (Fcy) receptors on macrophages, helping the body’s immune cells detect and fight tumors. The Company’s product pipeline in development includes Sonrotoclax, Tarlatamab, Zanidatamab, Blinatumomab, BGB-26808, BGB-R046, BG-68501, BG-C9074, BGB-43395, Xaluritamig, and others.
What is the current price of ONC stock?
The current stock price of ONC is 285.3 USD. The price decreased by -4.55% in the last trading session.
Does BEONE MEDICINES LTD-ADR pay dividends?
ONC does not pay a dividend.
How is the ChartMill rating for BEONE MEDICINES LTD-ADR?
ONC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the employee count for ONC stock?
BEONE MEDICINES LTD-ADR (ONC) currently has 11000 employees.
What is the market capitalization of ONC stock?
BEONE MEDICINES LTD-ADR (ONC) has a market capitalization of 31.57B USD. This makes ONC a Large Cap stock.
When does BEONE MEDICINES LTD-ADR (ONC) report earnings?
BEONE MEDICINES LTD-ADR (ONC) will report earnings on 2026-05-07.